1. Home
  2. PRME vs CMCO Comparison

PRME vs CMCO Comparison

Compare PRME & CMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

N/A

Current Price

$3.14

Market Cap

553.2M

Sector

Health Care

ML Signal

N/A

Logo Columbus McKinnon Corporation

CMCO

Columbus McKinnon Corporation

N/A

Current Price

$15.74

Market Cap

555.6M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
PRME
CMCO
Founded
2019
1875
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Construction/Ag Equipment/Trucks
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
553.2M
555.6M
IPO Year
2022
2002

Fundamental Metrics

Financial Performance
Metric
PRME
CMCO
Price
$3.14
$15.74
Analyst Decision
Buy
Buy
Analyst Count
6
2
Target Price
$7.56
$21.00
AVG Volume (30 Days)
2.7M
310.1K
Earning Date
05-08-2026
05-27-2026
Dividend Yield
N/A
1.90%
EPS Growth
18.18
N/A
EPS
N/A
N/A
Revenue
$4,632,000.00
$936,240,000.00
Revenue This Year
$7.06
$19.73
Revenue Next Year
$47.01
$82.91
P/E Ratio
N/A
N/A
Revenue Growth
55.28
3.27
52 Week Low
$2.67
$11.99
52 Week High
$6.94
$24.40

Technical Indicators

Market Signals
Indicator
PRME
CMCO
Relative Strength Index (RSI) 40.43 41.20
Support Level $2.73 $13.45
Resistance Level $3.72 $16.42
Average True Range (ATR) 0.21 0.70
MACD -0.06 -0.25
Stochastic Oscillator 11.63 8.16

Price Performance

Historical Comparison
PRME
CMCO

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

About CMCO Columbus McKinnon Corporation

Columbus McKinnon Corp is a world-wide designer, manufacturer and marketer of intelligent motion solutions for material handling that move the world forward and improve lives by efficiently and ergonomically moving, lifting, positioning and securing materials. Its key products include hoists, crane components, precision conveyor systems, rigging tools, light rail workstations and digital power and motion control systems. These are relevant, professional-grade solutions that solve its customers critical material handling requirements. The company has one operating and reportable segment. It has presence in United State, Germany, Europe, Middle East, and Africa (Excluding Germany), Canada, Asia Pacific, and Latin America. It has majority of sales from United States.

Share on Social Networks: